0.82
0.82 (0%)
As of Feb 14, 2025
Context Therapeutics Inc. [CNTX]
Source:
Company Overview
Context Therapeutics Inc. is a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies (“bsAb”) for solid tumors.
| Country | United States |
| Headquarters | philadelphia, pennsylvania |
| Phone Number | (267) 225-7416 |
| Industry | manufacturing |
| CEO | Martin Lehr |
| Website | www.contexttherapeutics.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-29.9 |
| Net Income | $-26.7 |
| Net Cash | $80 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -46.8% |
| Profit as % of Stockholder Equity | -28.1% |
Management Effectiveness
| Return on Equity | -28.1% |
| Return on Assets | -27.2% |
| Turnover Ratio | |
| EBITA | $-29.9 |
Balance Sheet and Cash Flow Measures
| Total Assets | $98.1 |
| Total Liabilities | $2.9 |
| Operating Cash Flow | $-14.6 |
| Investing Cash Flow | $-14.8 |
| Financing Cash Flow | $109.3 |
